Esperion Therapeutics | ESPR - Zinsaufwendungen Für Schuld

Aktienkurs
2.59
Täglich Wechseln
0.04 1.37%
Monatlich
-22.60%
Jährlich
52.96%
Q1 Prognose
2.47




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amarin USD 3K 5K 2024-12
Amgen USD 653M 32M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Cipla INR 140.3M 8.5M 2025-12
CSL USD 215M 111M 2025-12
Cytokinetics USD 30.33M 4.01M 2025-12
Daiichi Sankyo JPY 2.16B 1.33B 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Geron USD 7.3M 1.35M 2025-12
Grifols EUR 156.07M 31.46M 2025-09
Halozyme Therapeutics USD 4.91M 615K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Ionis Pharmaceuticals USD 18M 0 2025-12
Merck USD 412M 85M 2025-12
Minerva Neurosciences USD 2.31M 60K 2024-06
Moderna USD 12.14B 12.13B 2025-09
Nektar Therapeutics USD 6.02M 420K 2024-09
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Sanofi EUR -25M 252M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
United Therapeutics USD 3.1M 100K 2025-12
Vanda Pharmaceuticals 601.14M 23.61M 2025-09